SPA
GLUE icon

Sherbrooke Park Advisers’s Monte Rosa Therapeutics GLUE Stock Holding History

Sherbrooke Park Advisers’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-21,867
Closed -$98.6K – 600
2025
Q2 		$98.6K Buy
+21,867
New +$97.5K 0.04% 463
2025
Q1 		– Sell
-14,476
Closed -$100K – 732
2024
Q4 		$100K Sell
14,476
-5,517
-28% -$41.4K 0.03% 670
2024
Q3 		$106K Buy
+19,993
New +$101K 0.02% 832

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Sherbrooke Park Advisers's GLUE Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of Monte Rosa Therapeutics (GLUE) in Q3 2025, closing a stake of 21,867 shares — an estimated $98.6K sold.

Sherbrooke Park Advisers first reported a position in GLUE in Q3 2024 and held it in 3 quarters. The position peaked at $106K in Q3 2024. 129 funds tracked by Wall St. Rank hold GLUE as of Q3 2025.

  • Sherbrooke Park Advisers reported no remaining Monte Rosa Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 21,867 Monte Rosa Therapeutics shares in Q3 2025, an estimated $98.6K.
  • Sherbrooke Park Advisers first reported a position in Monte Rosa Therapeutics in Q3 2024 and held it in 3 quarters.
  • Sherbrooke Park Advisers's Monte Rosa Therapeutics position peaked at $106K in Q3 2024.
  • 129 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.